Current Opinion on Long-Lasting Therapy in CI-DME


  • Anna Nowińska "Chair and Clinical Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland" & "Ophthalmology Department, District Railway Hospital, Katowice, Poland "



Diabetes, Diabetic retinopathy, Diabetic macular edema, Anti-VEGF, Intravitreal injections, Treat and extend, Steroids


Diabetes has been recognized by the World Health Organization (WHO) as a noncommunicable, chronic disease and a 21st century epidemic. Diabetic retinopathy (DR) is one of the three leading causes of blindness among the working-age population aged 20 to 74 years.

Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients, and the impact of DME on quality of life is very significant. Currently, first-line treatment recommendations for center-involved DME (CI-DME) include intravitreal anti-VEGF injections on a monthly or bimonthly regimen. It is essential to understand the burden that treatment regimens have on patients, as well as on healthcare systems. The most significant improvement to the regimen would be to have fewer injections and monitoring visits while maintaining satisfactory vision outcomes. A lower number of intravitreal injections could optimize disease outcomes by improving patient compliance.

This article discusses novel agents targeting alternative pathways and mechanisms involved in the pathogenesis of DME, as well as high-dose drugs and novel approaches to treatment regimens aimed at extending treatment intervals, decreasing treatment burden, and increasing treatment efficacy. This knowledge will enhance the selection of treatments, thereby improving patient compliance with therapy and optimizing healthcare system resources.


Teo ZL, Tham YC, Yu M, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology 2021; 128: 1580-1591.

Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XIV. Ten-Year Incidence and Progression of Diabetic Retinopathy. Arch Ophthalmol 1994; 112: 1217-1228.

Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: III. Prevalence and Risk of Diabetic Retinopathy When Age at Diagnosis is 30 or More Years. Arch Ophthalmol 1984; 102: 527-532.

Mohamed Q, Gillies MC, Wong TY. Management of Diabetic Retinopathy. JAMA 2007; 298: 902.

Wong TY, Sun J, Kawasaki R, et al. Guidelines on Diabetic Eye Care. Ophthalmology 2018; 125: 1608-1622.

Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556-564.

Li JQ, Welchowski T, Schmid M, et al. Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis. Eur J Epidemiol 2020; 35: 11-23.

Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol 2016; 10: 939-946.

Piette JD, Kerr EA. The Impact of Comorbid Chronic Conditions on Diabetes Care. Diabetes Care 2006; 29: 725-731.

Holekamp NM, Campbell J, Almony A, et al. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. Am J Ophthalmol 2018; 191: 83-91.

Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol 2021; 105: 216-221.

Ehlken C, Helms M, Böhringer D, et al. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 2018; 12: 13-20.

Al Qassimi N, Kozak I, Al Karam M, et al. Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology. Ophthalmol Ther 2022; 11: 1937-1950.

Elman MJ, Aiello LP, Beck RW, et al. Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology 2010; 117: 1064-1077.e35.

Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405.

Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: A network meta-analysis. Cochrane Database of Systematic Reviews 2017; 2017: CD007419.

Ishibashi T, Li X, Koh A, et al. The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema. Ophthalmology 2015; 122: 1402-1415.

Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.

Virgili G, Parravano M, Menchini F, et al. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database of Systematic Reviews 2014; 2014: CD007419.

Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-2022.

Cheung GC, Yoon YH, Chen LJ, et al. Diabetic macular oedema: evidence-based treatment recommendations for Asian countries. Clin Experiment Ophthalmol 2018; 46: 75-86.

Yuen Y Sen, Gilhotra JS, Dalton M, et al. Diabetic Macular Oedema Guidelines: An Australian Perspective. J Ophthalmol 2023; 2023: 1-22.

Amoaku WM, Ghanchi F, Bailey C, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye 2020; 34: 1-51.

Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology 2020; 127: P66-P145.

Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2017; 237: 185-222.

Giridhar S, Verma L, Rajendran A, et al. Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement. Indian J Ophthalmol 2021; 69: 3076.

Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology 2016; 123: 1351-1359.

Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372: 1193-203.

Glassman AR, Wells JA, Josic K, et al. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology 2020; 127: 1201-1210.

Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol 2022; 238: 157-172.

Whitcup SM, Cidlowski JA, Csaky KG, et al. Pharmacology of Corticosteroids for Diabetic Macular Edema. Investig Opthalmology Vis Sci 2018; 59: 1.

Nguyen QD, Heier JS, Do D V., et al. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int J Retin Vitr 2020; 6: 48.

Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 2022; 399: 741-755.

Payne JF, Wykoff CC, Clark WL, et al. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Am J Ophthalmol 2019; 202: 91-99.

Prünte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol 2016; 100: 787-795.

Curry BA, Sanfilippo PG, Chan S, et al. Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice. Ophthalmol Ther 2020; 9: 87-101.

Kim YC, Shin JP, Pak KY, et al. Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema. Sci Rep 2020; 10: 22030.

Hirano T, Toriyama Y, Takamura Y, et al. Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema. Sci Rep 2021; 11: 4488.

Garweg JG, Štefanickova J, Hoyng C, et al. Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. Adv Ther 2022; 39: 2701-2716.

NCT04429503. I. Study of a high-dose aflibercept in participants with diabetic eye disease (PHOTON), (accessed 15 March 2023).

Regeneron. Aflibercept 8 MG Positive Pivotal Results in Diabetic Macular Edema and Wet Age-related Macular Degeneration Presented at AAO, (2022, accessed 15 March 2023).

Zur D, Iglicki M, Loewenstein A. The Role of Steroids in the Management of Diabetic Macular Edema. Ophthalmic Res 2019; 62: 231-236.

Boyer DS, Faber D, Gupta S, et al. Dexamethasone Intravitreal Implant for Treatment of Diabetic Macular Edema in Vitrectomized Patients. Retina 2011; 31: 915-923.

Boyer DS, Yoon YH, Belfort R, et al. Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema. Ophthalmology 2014; 121: 1904-1914.

Busch C, Zur D, Fraser-Bell S, et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol 2018; 55: 789-796.

Khan Z, Kuriakose RK, Khan M, et al. Effcacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: Meta-analysis and clinical implications. Ophthalmic Surg Lasers Imaging Retin 2017; 48: 160-166.

Kodjikian L, Bellocq D, Mathis T. Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. Biomed Res Int 2018; 2018: 8289253.

Augustin AJ, Bopp S, Fechner M, et al. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN ® (0.19 mg fluocinolone acetonide implant). Eur J Ophthalmol 2020; 30: 382-391.

Figueira J, Henriques J, Amaro M, et al. A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND). Ophthalmic Res 2017; 57: 166-172.

Munk MR, Somfai GM, de Smet MD, et al. The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. Int J Mol Sci 2022; 23: 7585.

Vitrectomy Outcomes in Eyes with Diabetic Macular Edema and Vitreomacular Traction. Ophthalmology 2010; 117: 1087-1093.e3.

Crim N, Velez-Montoya R, Morales-Canton V. Surgical Versus Medical Treatment for Diabetic Macular Edema: A Review. Med hypothesis, Discov Innov Ophthalmol J 2017; 6: 136-142.

Mansour SE, Browning DJ, Wong K, et al. The evolving treatment of diabetic retinopathy. Clinical Ophthalmology 2020; 14: 653-678.

Mehta H, Hennings C, Gillies MC, et al. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane database Syst Rev 2018; 4: CD011599.




How to Cite

Nowińska, A. . (2023). Current Opinion on Long-Lasting Therapy in CI-DME. Journal of Ocular Diseases and Therapeutics, 10, 1–10.